Ligand Pharmaceuticals opened lower at $316.57, compared with its previous close of $316.83. In the last trading session, the stock traded between $310.08 and $325.89. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Ligand Pharmaceuticals is now worth
$ 195.22
Giving a profit of
$ 95.22 (95.22%)
Note: Past profits do not guarantee future returns.
Rating from 8 Analysts
Today's Change
$-0.30 (-0.09%)
Day High
$325.89
Day Low
$310.08
Day Open
$316.57
Prev Close
$316.83
Volume
1,99,451
1W Return
0.09%
1M Return
1.66%
3M Return
9.66%
6M Return
43.57%
1Y Return
51.67%
Market Cap ($ Mn)
6,332
PE Ratio
29.59
PB Ratio
5.78
PEG Ratio
1.28
ROE
14.07%
ROCE
13.38%
EPS (TTM)
$-1.43
1 Week
0.09%
1 Month
1.66%
3 Months
9.66%
6 Months
43.57%
9 Months
70.22%
Barclays raises Ligand Pharmaceuticals price target to $350
Barclays maintains Overweight rating on Ligand Pharmaceuticals. Price target raised from $345 to $350. Analyst Glen Santangelo issued the rating update.
YesterdayLigand Pharmaceuticals sets Oct 29 date for Q3 2026 earnings
Ligand Pharmaceuticals will report Q3 2026 results on October 29, 2026. Conference call scheduled for 8:30 am Eastern time. Company holds interests in over 200 biopharmaceutical assets. Proprietary technologies include Captisol and NITRICIL.
28 days agoLigand Pharmaceuticals Q2 revenue rises 34% to $64 million
Total revenue rose 34% YoY to $64 million; royalty revenue grew 32% to $48 million. Adjusted diluted EPS increased 48% to $2.37, reflecting operational leverage. Closed XOMA Royalty acquisition, adding 120+ assets and expecting $1.50 EPS accretion in 2027. Completed $700 million zero-coupon convertible offering, retaining ~$700 million deployable capital. Raised low end of 2026 adjusted EPS guidance to $9.00, maintaining upper end at $9.50.
1mo agoLigand Pharmaceuticals stock returns 27% annually over last five years
Ligand Pharmaceuticals delivered a 27.11% average annual return over five years. The stock outperformed the broader market by 15.5% on an annualized basis. A $100 investment made five years ago is now worth $323.07. Ligand Pharmaceuticals has a current market capitalization of $5.67 billion.
1mo agoLigand Pharmaceuticals stock up 28.4% annually over past five years
Ligand Pharmaceuticals posted a 28.4% annualized return over five years. Stock outperformed the market by 17.28% on an annualized basis. Current market capitalization stands at $5.72 billion. A $100 investment from five years ago is now worth $349.06.
2mo agoLigand Pharmaceuticals to present at three investor conferences in September
Ligand Pharmaceuticals (NASDAQ: LGND) to speak at three investor conferences in September 2026. Management will hold a fireside chat at the Wells Fargo Healthcare Conference on September 8. A Citi Biopharma Back to School Conference presentation is scheduled for September 10. The company will also present at the H.C. Wainwright Global Investment Conference on September 14. One-on-one investor meetings can be arranged through respective bank representatives.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Ligand Pharmaceuticals is now worth
$ 195.22
Giving a profit of
$ 95.22 (95.22%)
Note: Past profits do not guarantee future returns.
